Actionable
Tissue
Intelligence
for Drug Development
Nucleai turns tissue into actionable intelligence: the evidence pharma needs to understand why a therapy works and which patients are most likely to benefit.
We read tissue across H&E, IHC, mIF, and spatial transcriptomics with AI-driven multimodal analysis, and connect what we find to clinical outcomes.
What Tissue Intelligence Means
Tissue intelligence brings together computational pathology, spatial biology, and multimodal image analysis, then
links what the tissue shows to clinical outcomes.
The result is structured, traceable evidence that translational
and biomarker teams can use to support program decisions, not another expression score to interpret.
Multimodal by design
Integrate H&&E, IHC,mIF, and spatial transcriptomics.
AI-powered insights
Advanced models reveal biology at cellular context.
Linked to outcomes
Connect tissue features to clinical outcomes.
Traceable & explainable
Transparent, reproducible outputs you can trust and audit.
Who We Work with
We work with biopharma sponsors wherever tissue biology is central to a program decision, across oncology,
immunology and inflammation, and [disease area pending item 3], and modalities including ADCs,
immuno-oncology, T-cell engagers, and multispecifics.
Our work supports translational medicine, clinical biomarker, and translational pathology teams.
Nucleai and Gilead Sciences: tissue intelligence in ADC development
An ongoing translational research collaboration supporting Gilead's global ADC clinical development programs,
analyzing H&E and IHC whole-slide images across several clinical studies and multiple oncology indications,
integrated with clinical outcomes data.
Trusted by Leading Biopharma
Our partnership with Nucleai will help us accelerate the translation of spatial biology insights into clinical practice, ultimately improving patient care.
Nigel Jamieson, Professor of Hepatobiliary and Pancreatic Surgery
University of Glasgow
Nucleai’s technology stands out by being the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program.
Noga Yerushalmi, PhD, Investment Director
M Ventures (Corporate Strategic Venture Arm of Merck KGaA, Darmstadt, Germany)
of the Top 20 biopharma
12
+
clinical trial studies
30
+
indications
10
+
Data and Institutional Partners
Our
AI Technology
Our platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, multiplex immunofluorescence, and spatial transcriptomics), conducts advanced spatial analysis, and delivers actionable insights. These insights optimize biomarker scoring, determine biomarker prevalence and mechanism of action (MoA), and predict response to therapy, revolutionizing our approach to disease diagnosis and treatment.
The Power of
AI Spatial Biomarkers
In this educational talk, Kenneth J Bloom, MD, FCAP, explains the evolution of precision medicine and how AI-driven spatial biomarkers can power the next-generation of therapeutics and improve patient outcomes.
Investors
Join Us in
Transforming Patient Care
At Nucleai, we bring together leading minds in pathology, medicine, biology, engineering, and artificial intelligence to tackle the most complex challenges in healthcare, with the goal of transforming patient care. Come join our team to revolutionize precision medicine.